You Own Wall Street › Funds › T. Rowe Price Health Care ETF
T. Rowe Price Health Care ETF (TMED) proxy voting record 2026
Three of its ballots from this season. Vote first, then see what it did with the shares your savings paid for.
The question on the ballot
As filed
T. Rowe Price Exchange-Traded Funds files this fund's proxy votes with the SEC once a year. This is what it did with the shares your retirement savings paid for.
SourceProxy-voting record filed by T. Rowe Price Exchange-Traded Funds on 2026-08-28 · open the filing · vote table (ProxyVotingTable.xml, 37 MB)
TickerTMED · as listed in its latest SEC filing of proxy votes
How it voted, by issue
Fund companies sometimes file the same proposal under different subjects. So that funds can be compared, each proposal is counted under the subject most of the filings we read gave it, the same for every fund on this site. On management's own executive pay resolutions, this fund voted in favour 90.7% of the time across 75 votes.
| Issue | Proposals faced | Backed | Share backed |
|---|---|---|---|
| Climate & environment | 1 | 0 | 0% |
| Executive pay | 1 | 0 | 0% |
| Corporate governance | 8 | 2 | 25% |
| Other social issues | 2 | 0 | 0% |
Ballots it voted
Gilead Sciences, Inc. · 30 April 2026 · put on the ballot by shareholder · Climate & environment
A report on the risks of ESG and DEI executive compensation metrics
AGAINST T. Rowe Price Health Care ETF voted with 4,771 shares
“To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.”
SourceT. Rowe Price Exchange-Traded Funds, Form N-PX filed 2026-08-28 · accession 0001193125-26-372784 · series S000092023 · open the filing
Humana Inc. · 16 April 2026 · put on the ballot by shareholder · Executive pay
Should shareholders get a vote before Humana pays a departing executive?
Shareholders asked the company to seek shareholder approval for any severance package to a senior executive above a set multiple of salary and bonus — so that very large exit payments cannot be agreed by the board alone.
AGAINST T. Rowe Price Health Care ETF voted with 1,758 shares
“The stockholder proposal requesting shareholder approval requirement for excessive golden parachutes, if properly presented at the meeting.”
SourceT. Rowe Price Exchange-Traded Funds, Form N-PX filed 2026-08-28 · accession 0001193125-26-372784 · series S000092023 · open the filing
Gilead Sciences, Inc. · 30 April 2026 · put on the ballot by shareholder
Should the person who runs Gilead Sciences also chair the board that supervises them?
Shareholders asked the company to require that the chair of the board be an independent director rather than the chief executive, so that the body overseeing management is not led by the person being overseen.
AGAINST T. Rowe Price Health Care ETF voted with 4,771 shares
“To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.”
SourceT. Rowe Price Exchange-Traded Funds, Form N-PX filed 2026-08-28 · accession 0001193125-26-372784 · series S000092023 · open the filing
UnitedHealth Group Incorporated · 1 June 2026 · put on the ballot by shareholder
AGAINST T. Rowe Price Health Care ETF voted with 4,508 shares
“If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent.”
SourceT. Rowe Price Exchange-Traded Funds, Form N-PX filed 2026-08-28 · accession 0001193125-26-372784 · series S000092023 · open the filing
Eli Lilly and Company · 4 May 2026 · put on the ballot by shareholder · Social
Should Eli Lilly and disclose what it lobbies for?
Shareholders asked for a report on the company’s lobbying: what it spends, which trade associations receive its money, what positions those bodies take, and who inside the company decides.
AGAINST T. Rowe Price Health Care ETF voted with 2,897 shares
“Shareholder proposal to prepare an annual lobbying report.”
SourceT. Rowe Price Exchange-Traded Funds, Form N-PX filed 2026-08-28 · accession 0001193125-26-372784 · series S000092023 · open the filing
Gilead Sciences, Inc. · 30 April 2026 · put on the ballot by shareholder · Social
A report on the impact of extended patent exclusivities on patient access
AGAINST T. Rowe Price Health Care ETF voted with 4,771 shares
“To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.”
SourceT. Rowe Price Exchange-Traded Funds, Form N-PX filed 2026-08-28 · accession 0001193125-26-372784 · series S000092023 · open the filing
Other funds T. Rowe Price Exchange-Traded Funds votes
The same filer reports these alongside this one, in the same annual filing.
No 401(k) plan we index offers this fund. Its record is here because the fund files it with the SEC, as every fund must: whoever holds it, in an IRA, a brokerage account or a plan we have not indexed, the fund votes those shares as shown on this page.